REGN - Regeneron Pharmaceuticals, Inc.


Strong Growth but Declining


based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is -10.94%
Operating Income Growth is -36.78%
Net Income Growth is -24.4%
Earnings Per Share (EPS) Growth is -24.5%
Net Margin is 33.93%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 5.45
Debt Ratio is 0.22
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.06
Cash Flow is MODERATE
Cash from Operations Growth is -43.93%
Capital Expenditure is Low
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is Low
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Regeneron Pharmaceuticals, Inc. (REGN) -
Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, its unique ability to repeatedly and consistently translate science into medicine has led to nine FDA-approved treatments and numerous product candidates in development, almost all of which were homegrown in its laboratories. Its medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.
Exchange - NASDAQ
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Leonard Schleifer
Employees - 11,851



Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2023 and future.